Product Code: GMDHC10244IDB
Summary:
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus - Pipeline Review, H1 2018, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.
Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.
Report Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 6, 4, 5, 2 and 9 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.
Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Tetanus - Overview
- Tetanus - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Tetanus - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tetanus - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Bharat Biotech International Ltd
- Biological E Ltd
- Cadila Healthcare Ltd
- GC Pharma
- GlaxoSmithKline Plc
- Indian Immunologicals Ltd
- Kaketsuken
- LG Chem Ltd
- Panacea Biotec Ltd
- Sanofi
- Sanofi Pasteur SA
- Serum Institute of India Ltd
- Shantha Biotechnics Pvt Ltd
- Wockhardt Ltd
- Tetanus - Drug Profiles
- (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BK-1310 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- DTcP vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GC-3111A - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- KD-370 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LBVD - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibody for Tetanus - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tetanus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tetanus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tetanus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Tetanus - Dormant Projects
- Tetanus - Discontinued Products
- Tetanus - Product Development Milestones
- Featured News & Press Releases
- Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine - Hexaxim
- Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine- Hexaxim
- Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
- Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
- Nov 10, 2014: Shantha's Pentavalent Pediatric Vaccine launched in India
- Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
- May 05, 2014: Shantha's Pentavalent Pediatric Vaccine prequalified by World Health Organization
- Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima
- Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine
- Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Pediatric Vaccine In European Markets
- Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency
- May 11, 2011: Sanofi Pasteur Launches Pentaxim In China
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development for Tetanus, H1 2018
- Number of Products under Development by Companies, H1 2018
- Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
- Number of Products under Development by Universities/Institutes, H1 2018
- Products under Development by Companies, H1 2018
- Products under Development by Companies, H1 2018 (Contd..1), H1 2018
- Products under Development by Universities/Institutes, H1 2018
- Number of Products by Stage and Target, H1 2018
- Number of Products by Stage and Mechanism of Action, H1 2018
- Number of Products by Stage and Route of Administration, H1 2018
- Number of Products by Stage and Molecule Type, H1 2018
- Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018
- Tetanus - Pipeline by Bharat Biotech International Ltd, H1 2018
- Tetanus - Pipeline by Biological E Ltd, H1 2018
- Tetanus - Pipeline by Cadila Healthcare Ltd, H1 2018
- Tetanus - Pipeline by GC Pharma, H1 2018
- Tetanus - Pipeline by GlaxoSmithKline Plc, H1 2018
- Tetanus - Pipeline by Indian Immunologicals Ltd, H1 2018
- Tetanus - Pipeline by Kaketsuken, H1 2018
- Tetanus - Pipeline by LG Chem Ltd, H1 2018
- Tetanus - Pipeline by Panacea Biotec Ltd, H1 2018
- Tetanus - Pipeline by Sanofi, H1 2018
- Tetanus - Pipeline by Sanofi Pasteur SA, H1 2018
- Tetanus - Pipeline by Serum Institute of India Ltd, H1 2018
- Tetanus - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2018
- Tetanus - Pipeline by Wockhardt Ltd, H1 2018
- Tetanus - Dormant Projects, H1 2018
- Tetanus - Dormant Projects, H1 2018 (Contd..1), H1 2018
- Tetanus - Discontinued Products, H1 2018
List of Figures
- Number of Products under Development for Tetanus, H1 2018
- Number of Products under Development by Companies, H1 2018
- Number of Products under Development by Universities/Institutes, H1 2018
- Number of Products by Targets, H1 2018
- Number of Products by Stage and Targets, H1 2018
- Number of Products by Stage and Mechanism of Actions, H1 2018
- Number of Products by Routes of Administration, H1 2018
- Number of Products by Stage and Routes of Administration, H1 2018
- Number of Products by Molecule Types, H1 2018
- Number of Products by Stage and Molecule Types, H1 2018
